SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

Read more breaking news

 

 

Drug design made easier by advanced NMR method

By Staff Reporter , 24-Nov-2006

Scientists have managed to gain unique insights into the future design of drugs for a selection of medical conditions using innovative NMR equipment to study a range of biological processes.

The technique uses nuclear magnetic resonance (NMR) spectroscopy - a long established tool for determining the structure of small molecules, made more versatile by recent advances in the field.

Bigger and more powerful spectrometers with higher magnetic field strengths offer new insights into the reactions, which can aid in future drug development and research.

A group including Professor Malthouse and Dr Chandralal Hewage, NMR scientist at the NMR Centre in UCD Conway Institute, used NMR technology to solve the 3D solution structure of the gastrointestinal polypeptide GIP.

GIP is a hormone that stimulates the secretion of insulin after ingestion of food and has been linked to diabetes and obesity-related diseases.

A 3D picture of the protein was built step-by-step using a range of NMR experiments and molecular modelling calculations.

Two-dimensional NMR spectra revealed information about the connectivities of the atoms, allowing the identity of each amino acid residue to be determined.

Enzymes, like other proteins, were traditionally characterised in the solid state by X-ray crystallography.

NMR has the advantage as biomolecules can now be studied in their natural environment in bodily fluids and even in cell membranes using solid state NMR.

Protein-digesting enzymes called proteases play a role in propagating the AIDS virus, in allowing cancers and parasites to move through tissues and in the production of the plaque protein, which causes Alzheimer's disease.

Inhibiting these enzymes is key to treating such diseases. Drugs are designed to target enzymes by slotting into their active sites and shutting them down. Drug design seeks to optimise inhibitor binding, so we need to understand how the inhibitors interact with an enzyme.

"We are synthesising protease inhibitors and using NMR to determine how they interact with specific proteases. By studying these interactions we hope to see ways of optimising an inhibitor's ability to inhibit the specific protease involved in a given disease," said Professor Paul Malthouse, principal investigator with the Centre for Synthesis and Chemical Biology and UCD Conway Institute

It is essential that potent protease inhibitors designed will only target the protease involved in the disease and not those, which are essential for the human body.

"We are currently starting to synthesise and characterise a range of inhibitors which we hope will provide important insights into the development of drugs to treat a range of medical conditions," added Malthouse.

Understanding the structural requirements for the biological activity of GIP will help in the design of new drugs for diabetes and obesity related disorders.

"Proteins are huge molecules but commercially viable drugs need to be a lot smaller both for ease of entry into cells and because of the manufacturing costs involved," said Dr Hewage.

"Once the structure of the protein is known, the important residues can be identified and a smaller drug molecule synthesised."

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...